At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Company profile
Ticker
BIIB
Exchange
Website
CEO
Michel Vounatsos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
Corporate docs
Subsidiaries
Biogen Foundation Inc. • Biogen MA Inc. • Biogen Realty Corporation • Biogen Realty Limited Partnership • Biogen U.S. Corporation • Biogen U.S. Limited Partnership • BDH U.S. Holdco Inc. • Biogen (RTP) Realty LLC • Biogen Chesapeake LLC • Biogen Digital Health Inc. ...
IRS number
330112644
BIIB stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
3 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
ARS
2023 FY
Annual report to shareholders
28 Apr 23
10-Q
2023 Q1
Quarterly report
25 Apr 23
8-K
Company reports first quarter 2023 results and reaffirms full year 2023 guidance
25 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Apr 23
8-K
Departure of Directors or Certain Officers
8 Mar 23
10-K
2022 FY
Annual report
15 Feb 23
8-K
Biogen advances significant potential growth drivers; Company reports full year 2022 results and provides full year 2023 guidance
15 Feb 23
Transcripts
BIIB
Earnings call transcript
2023 Q1
25 Apr 23
BIIB
Earnings call transcript
2022 Q4
15 Feb 23
BIIB
Earnings call transcript
2022 Q3
25 Oct 22
BIIB
Earnings call transcript
2022 Q2
20 Jul 22
BIIB
Earnings call transcript
2022 Q1
3 May 22
BIIB
Earnings call transcript
2021 Q4
3 Feb 22
BIIB
Earnings call transcript
2021 Q3
20 Oct 21
BIIB
Earnings call transcript
2021 Q2
22 Jul 21
BIIB
Earnings call transcript
2021 Q1
22 Apr 21
BIIB
Earnings call transcript
2020 Q4
3 Feb 21
Latest ownership filings
4
Adam Keeney
2 May 23
4
Ginger Gregory
2 May 23
144
Notice of proposed sale of securities
28 Apr 23
3
Adam Keeney
25 Apr 23
4
Priya Singhal
6 Apr 23
4
Nicole Murphy
4 Apr 23
144
Notice of proposed sale of securities
4 Apr 23
4
Priya Singhal
30 Mar 23
144
Notice of proposed sale of securities
28 Mar 23
4
Priya Singhal
6 Mar 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.90 bn | 2.90 bn | 2.90 bn | 2.90 bn | 2.90 bn | |
| Cash burn (monthly) | 173.70 mm | (no burn) | (no burn) | (no burn) | (no burn) | |
| Cash used (since last report) | 340.35 mm | n/a | n/a | n/a | n/a | |
| Cash remaining | 2.56 bn | n/a | n/a | n/a | n/a | |
| Runway (months of cash) | 14.7 | n/a | n/a | n/a | n/a | |
Institutional ownership, Q1 2023
85.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 949 |
| Opened positions | 82 |
| Closed positions | 126 |
| Increased positions | 326 |
| Reduced positions | 343 |
| 13F shares | Current |
|---|---|
| Total value | 33.92 tn |
| Total shares | 124.40 mm |
| Total puts | 1.95 mm |
| Total calls | 2.26 mm |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Primecap Management | 16.00 mm | $4.45 tn |
| BLK Blackrock | 13.99 mm | $3.89 tn |
| Vanguard | 12.16 mm | $3.38 tn |
| STT State Street | 6.76 mm | $1.88 tn |
| Wellington Management | 5.45 mm | $1.52 tn |
| JPM JPMorgan Chase & Co. | 4.11 mm | $1.14 tn |
| Geode Capital Management | 3.10 mm | $860.78 bn |
| Envestnet Asset Management | 2.56 mm | $90.40 bn |
| T. Rowe Price | 2.09 mm | $581.22 bn |
| Clearbridge Advisors | 1.86 mm | $518.46 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 May 23 | Adam Keeney | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,815 | 0.00 | 2,815 |
| 28 Apr 23 | Ginger Gregory | Common Stock | Sell | Dispose S | No | No | 300 | 2,681 | 804.30 k | 8,482.716 |
| 4 Apr 23 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 277.11 | 91 | 25.22 k | 2,843.092 |
| 31 Mar 23 | Nicole Murphy | Common Stock | Payment of exercise | Dispose F | No | No | 278.03 | 116 | 32.25 k | 5,702.29 |
| 31 Mar 23 | Nicole Murphy | Common Stock | Option exercise | Acquire M | No | No | 0 | 239 | 0.00 | 5,818.29 |
| 31 Mar 23 | Nicole Murphy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 239 | 0.00 | 240 |
News
Biogen Unusual Options Activity For May 26
26 May 23
Analyst Ratings for Biogen
23 May 23
Wedbush Reiterates Neutral on Biogen, Maintains $263 Price Target
23 May 23
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
19 May 23
Health Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease
16 May 23
Press releases
HEALTH CANADA ACCEPTS NEW DRUG SUBMISSION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE
18 May 23
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
15 May 23
Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium
15 May 23
PureTech Announces Annual Results for Year Ended December 31, 2022
28 Apr 23
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
25 Apr 23